MannKind Corporation (MNKD)
| Bid | 4.6 |
| Market Cap | 1.51B |
| Revenue (ttm) | 285.5M |
| Net Income (ttm) | 27.59M |
| EPS (ttm) | 0.1 |
| PE Ratio (ttm) | 49.55 |
| Forward PE | 19.42 |
| Analyst | Buy |
| Ask | 5.2 |
| Volume | 1,121,739 |
| Avg. Volume (20D) | 2,047,493 |
| Open | 5.03 |
| Previous Close | 5.04 |
| Day's Range | 4.87 - 5.05 |
| 52-Week Range | 4.17 - 7.63 |
| Beta | 1.21 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a licens...
Analyst Forecast
According to 6 analyst ratings, the average rating for MNKD stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 71.54% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In QuestionMannKind's stock has fluctuated due to Tyvaso DPI's Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI's potential ...
